BDSX•Biodesix reported third-quarter revenue up 10% year over year to $24.04 million and net loss down 8% to $8.03 million. It revised full-year 2026 revenue guidance to $101 million–$103 million.
Biodesix said third-quarter 2026 revenue rose 10% year over year to $24.04 million, while its net loss narrowed 8% to $8.03 million. Development Services revenue fell 49% to $986,000, reflecting project completion and revenue-recognition timing. CEO Scott Hutton attributed below-expected growth partly to fewer sales representatives contributing than planned and greater-than-anticipated seasonality. The company revised full-year revenue guidance to $101 million–$103 million.
